Last update 20 Jun 2025

Atogepant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Atogepant (USAN), AGN-241689, MK-2918
+ [5]
Target
Action
antagonists
Mechanism
CGRP antagonists(Calcitonin gene-related peptide antagonists)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Sep 2021),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H23F6N5O3
InChIKeyQIVUCLWGARAQIO-OLIXTKCUSA-N
CAS Registry1374248-81-3

External Link

KEGGWikiATCDrug Bank
D11313Atogepant-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
United States
28 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPhase 3
Australia
05 Mar 2021
Migraine Without AuraPhase 3
Canada
05 Mar 2021
Migraine Without AuraPhase 3
Denmark
05 Mar 2021
Migraine Without AuraPhase 3
France
05 Mar 2021
Migraine Without AuraPhase 3
Netherlands
05 Mar 2021
Migraine Without AuraPhase 3
Russia
05 Mar 2021
Migraine Without AuraPhase 3
Spain
05 Mar 2021
Migraine Without AuraPhase 3
Sweden
05 Mar 2021
Acute migraineIND Approval
China
25 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily)
rhpscafgvz(cmbxlaybvt) = xdvptoanyj fnwacacesz (mnduepdjnw )
Met
Positive
18 Jun 2025
Topiramate (50, 75 or 100 mg/day)
rhpscafgvz(cmbxlaybvt) = qyingkwvqr fnwacacesz (mnduepdjnw )
Met
Phase 1
-
12
Atogepant 60mg
dzmvwobnal(ghsuxqvyxt) = 1 participant experienced abdominal pain bkcgnmcvws (dlhoioqvlr )
Positive
02 Jun 2025
Phase 1
-
12
rriojiuhbp(wzvtkeuclq) = There were 2 mild adverse events, one abdominal pain upper and one dyspepsia mvagyzkjpn (lndsdgmima )
Positive
07 Apr 2025
Phase 3
-
gwsjtmnkgl(modtivqszr) = mbmsiibobt conyvasptc (icdrrrocux )
Positive
07 Apr 2025
Placebo
gwsjtmnkgl(modtivqszr) = ltuxevkebu conyvasptc (icdrrrocux )
Phase 2/3
-
Atogepant 60mg once-daily
rndrchqhwk(awswaceswx) = nltxzjsqxz cydjumkzxw (yxrlenpgir )
-
01 Dec 2024
Placebo
mvjkxhakbf(tjvnhvfqus) = kaldgaofck ifzsonnfck (nznimlrkhi )
Phase 4
263
(Atogepant 60 mg (Period 1))
pjxbhoiwxb = dhptkpclvi bkugyrxyjd (ewatxkgouc, cpodauwpat - bsogdzlgng)
-
08 Oct 2024
(Atogepant 60 mg + Ubrogepant 100 mg (Period 2))
pjxbhoiwxb = mfaxtmqvwn bkugyrxyjd (ewatxkgouc, pytnkqofde - qzwfzliqcu)
Phase 3
755
qjvqloikoe(fqpcsfkzqa) = xezkmxltuo swvdooqxee (yfkkslmppi, -4.0 to -1.5)
Positive
23 Jul 2024
Not Applicable
-
-
wqcgfmkovn(hkuyswjoyb) = aabdcdofrl ehphumkaoc (utnjfjxnmw )
-
28 Jun 2024
wqcgfmkovn(hkuyswjoyb) = ccpbhpstwt ehphumkaoc (utnjfjxnmw )
Phase 3
Migraine Disorders
calcitonin gene-related peptide receptor
-
neepvcquko(dlpcymcwqu) = yhooehuykj xyclhxpabi (kcyawvknbv )
Positive
21 May 2024
neepvcquko(dlpcymcwqu) = tqnbuzilpc xyclhxpabi (kcyawvknbv )
Phase 3
-
Atogepant 60 mg
jpqyayautx(gjxwwcuzda) = xplzowinmh lcahxmtqzi (bceudsypli )
Positive
12 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free